166 related articles for article (PubMed ID: 1324767)
1. Spinal mechanisms of delta 9-tetrahydrocannabinol-induced analgesia.
Smith PB; Martin BR
Brain Res; 1992 Apr; 578(1-2):8-12. PubMed ID: 1324767
[TBL] [Abstract][Full Text] [Related]
2. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice.
Varvel SA; Bridgen DT; Tao Q; Thomas BF; Martin BR; Lichtman AH
J Pharmacol Exp Ther; 2005 Jul; 314(1):329-37. PubMed ID: 15831444
[TBL] [Abstract][Full Text] [Related]
3. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide.
Houser SJ; Eads M; Embrey JP; Welch SP
Brain Res; 2000 Feb; 857(1-2):337-42. PubMed ID: 10700588
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of agonist-antagonist properties of nitrogen mustard and cyano derivatives of delta 8-tetrahydrocannabinol.
Wiley JL; Compton DR; Gordon PM; Siegel C; Singer M; Dutta A; Lichtman AH; Balster RL; Razdan RK; Martin BR
Neuropharmacology; 1996; 35(12):1793-804. PubMed ID: 9076759
[TBL] [Abstract][Full Text] [Related]
5. Interactions between THC and cannabidiol in mouse models of cannabinoid activity.
Varvel SA; Wiley JL; Yang R; Bridgen DT; Long K; Lichtman AH; Martin BR
Psychopharmacology (Berl); 2006 Jun; 186(2):226-34. PubMed ID: 16572263
[TBL] [Abstract][Full Text] [Related]
6. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception.
Welch SP; Dunlow LD; Patrick GS; Razdan RK
J Pharmacol Exp Ther; 1995 Jun; 273(3):1235-44. PubMed ID: 7791096
[TBL] [Abstract][Full Text] [Related]
7. The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord.
Pugh G; Smith PB; Dombrowski DS; Welch SP
J Pharmacol Exp Ther; 1996 Nov; 279(2):608-16. PubMed ID: 8930163
[TBL] [Abstract][Full Text] [Related]
8. The pharmacological activity of inhalation exposure to marijuana smoke in mice.
Lichtman AH; Poklis JL; Poklis A; Wilson DM; Martin BR
Drug Alcohol Depend; 2001 Jul; 63(2):107-16. PubMed ID: 11376914
[TBL] [Abstract][Full Text] [Related]
9. Physiochemical and pharmacological characterization of a Delta(9)-THC aerosol generated by a metered dose inhaler.
Wilson DM; Peart J; Martin BR; Bridgen DT; Byron PR; Lichtman AH
Drug Alcohol Depend; 2002 Aug; 67(3):259-67. PubMed ID: 12127197
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid-induced antinociception is mediated by a spinal alpha 2-noradrenergic mechanism.
Lichtman AH; Martin BR
Brain Res; 1991 Sep; 559(2):309-14. PubMed ID: 1665384
[TBL] [Abstract][Full Text] [Related]
11. Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212.
Fan F; Compton DR; Ward S; Melvin L; Martin BR
J Pharmacol Exp Ther; 1994 Dec; 271(3):1383-90. PubMed ID: 7996450
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological evaluation of halogenated delta 8-THC analogs.
Charalambous A; Lin S; Marciniak G; Banijamali A; Friend FL; Compton DR; Martin BR; Makriyannis A
Pharmacol Biochem Behav; 1991 Nov; 40(3):509-12. PubMed ID: 1666915
[TBL] [Abstract][Full Text] [Related]
13. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine.
Welch SP; Thomas C; Patrick GS
J Pharmacol Exp Ther; 1995 Jan; 272(1):310-21. PubMed ID: 7815346
[TBL] [Abstract][Full Text] [Related]
14. Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice.
Bass CE; Martin BR
Drug Alcohol Depend; 2000 Aug; 60(2):113-9. PubMed ID: 10940538
[TBL] [Abstract][Full Text] [Related]
15. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord.
Pugh G; Mason DJ; Combs V; Welch SP
J Pharmacol Exp Ther; 1997 May; 281(2):730-7. PubMed ID: 9152379
[TBL] [Abstract][Full Text] [Related]
16. Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism.
Hayakawa K; Mishima K; Hazekawa M; Sano K; Irie K; Orito K; Egawa T; Kitamura Y; Uchida N; Nishimura R; Egashira N; Iwasaki K; Fujiwara M
Brain Res; 2008 Jan; 1188():157-64. PubMed ID: 18021759
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
Compton DR; Little PJ; Martin BR; Gilman JW; Saha JK; Jorapur VS; Sard HP; Razdan RK
J Med Chem; 1990 May; 33(5):1437-43. PubMed ID: 2158563
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological potency of R- and S-3'-hydroxy-delta 9-tetrahydrocannabinol: additional structural requirement for cannabinoid activity.
Martin BR; Kallman MJ; Kaempf GF; Harris LS; Dewey WL; Razdan RK
Pharmacol Biochem Behav; 1984 Jul; 21(1):61-5. PubMed ID: 6087379
[TBL] [Abstract][Full Text] [Related]
19. Functional effects of synthetic cannabinoids versus Δ
Schreiber S; Bader M; Lenchinski T; Meningher I; Rubovitch V; Katz Y; Cohen E; Gabet Y; Rotenberg M; Wolf EU; Pick CG
Addict Biol; 2019 May; 24(3):414-425. PubMed ID: 29423994
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents.
Compton DR; Johnson MR; Melvin LS; Martin BR
J Pharmacol Exp Ther; 1992 Jan; 260(1):201-9. PubMed ID: 1309872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
